[1] SIEGEL R L,MILLER K D,JEMAL A. Cancer statistics,2019[J].CA ACancer J Clin,2019,69(1):7-34. [2] CHEN W Q,ZHENG R S,BAADE P D,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin, 2016,66(2):115-132. [3] SANZ M A,MONTESINOS P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia[J]. Blood,2014,123(18):2777-2782. [4] HUANG Y,QIU JH,CHEN GQ, et al. Coiled-coil domain of PML is essential for the aberrant dynamics of PML-RARalpha, resulting in sequestration and decreased mobility of SMRT[J]. Biochem Biophys Res Commun,2008,365(2):258-265. [5] LO-COCO F,HASAN S K. Understanding the molecular pathogenesis of acute promyelocytic leukemia[J]. Best Pract Res Clin Haematol,2014,27(1):3-9. [6] ARBER D A,ORAZI A,HASSERJIAN R,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016,127(20):2391-2405. [7] BABA S M,PANDITH A A,SHAH Z A,et al. Pathogenetic implication of fusion genes in acute promyelocytic leukemia and their diagnostic utility[J]. Clin Genet,2019,95(1):41-52. [8] LI S F,CHEN L,JIN W,et al. Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia:A meta-analysis[J]. Sci Rep,2017,7(1):17998. [9] BRECCIA M,MAZZARELLA L,BAGNARDI V,et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols[J]. Blood,2012,119(1):49-54. [10] BARBUI T,FINAZZI G,FALANGA A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia[J]. Blood,1998,91(9):3093-3102. [11] SAEED S,LOGIE C,STUNNENBERG G,et al. Genome-wide functions of PML-RARα in acute promyelocytic leukaemia[J]. Br J Cancer,2011,104(4):554-558. [12] UY G L,LANE A A,WELCH J S,et al. A protease-resistant PML-RARαhas increased leukemogenic potential in a murine model of acute promyelocytic leukemia[J]. Blood,2010,116(18):3604-3610. [13] FIELDS S,SONG O. A novel genetic system to detect protein-protein interactions[J]. Nature, 1989, 340(6230):245-246. [14] WANG K,LI S,GAO Y, et al. BCL3 regulates RANKL-induced osteoclastogenesis by interacting with TRAF6 in bone marrow-derived macrophages[J]. Bone, 2018,114:257-267. [15] LU W T,YU T T,LIU S,et al. FHL2 interacts with iASPP and impacts the biological functions of leukemia cells[J]. Oncotarget,2017,8(25):40885-40895. [16] LIN D Y, HUANG C C, HSIEH Y T, et al. Analysis of the interaction between Zinc finger protein 179(Znf179) and promyelocytic leukemia zinc finger (Plzf)[J]. J Biomed Sci,2013,20:98. [17] 高艳军,刘北忠,钟梁,等.GINS2基因siRNA真核表达质粒的构建及其对NB4细胞凋亡的影响[J].中国生物制品学杂志,2012,25(12):1602-1606. [18] 张曦,刘北忠,高艳军,等.干扰GINS2表达对HL60细胞增殖和凋亡的影响[J].中国生物工程杂志,2013,33(3):41-46. [19] GAO Y J,WANG S B,LIU B Z,et al. Roles of GINS2 in K562 human chronic myelogenous leukemia and NB4 acute promyelocytic leukemia cells[J]. Int J Mol Med,2013,31(6):1402-1410. [20] ZHANG X,ZHONG L,LIU B Z,et al. Effect of GINS2 on proliferation and apoptosis in leukemic cell line[J]. Int J Med Sci,2013,10(12):1795-1804. |